List of works - Vincenza Calvaruso

A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation

scientific article published on 17 November 2009

Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy

scientific article published on 25 September 2019

An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

scientific article published on 20 June 2014

An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers.

scientific article published on 26 August 2009

Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

article

Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication.

scientific article

Clinical implications of the hyperdynamic syndrome in cirrhosis

scientific article published on 20 September 2014

Coagulation and fibrosis in chronic liver disease

scientific article

Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis

scientific article published on 6 March 2015

Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis.

scientific article published on 17 November 2015

Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis

scientific article

Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C.

scientific article published on 4 October 2011

Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient.

scientific article published on April 2009

Critically ill patients with cirrhosis and low serum sodium

scientific article published on 01 August 2010

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

scientific article published in Scientific Reports

Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial

scientific article

Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation.

scientific article published on 20 December 2012

Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation

scientific article

Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

scientific article published on 06 April 2019

Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?

scientific article published on 21 February 2016

Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension

scientific article

Efficacy and safety of Boceprevir-based therapy in HCVG1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP survey

article

Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy

scientific article published in September 2010

Fecal Calprotectin in Clinical Practice

scientific article published on 01 July 2012

Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance.

scientific article published on 11 May 2013

Fibrosis in chronic viral hepatitis.

scientific article published on April 2011

Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy.

scientific article published on 25 September 2009

HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.

scientific article published on 13 July 2017

HBV recurrence after HCV clearance on DAAs: Sometimes they come back

scientific article published on 29 August 2017

Hepassocin as a treatment for fulminant hepatic failure: will it translate from rats to human?

scientific article published on 01 June 2010

Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis

scientific article published on 15 July 2020

Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis

scientific article published on 2 March 2018

Hepatocellular carcinoma and direct-acting antivirals: A never ending story?

scientific article published in June 2017

High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma

scientific article published on 03 May 2018

Histological subclassification of cirrhosis

scientific article published on 01 August 2010

IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection

scientific article

Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin

scientific article published on 20 August 2013

Immunological alterations in hepatitis C virus infection

scientific article

Impact of tips preliver transplantation for the outcome posttransplantation

scientific article published on 27 November 2008

Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model

scientific article published on 10 May 2016

Implication of normal liver enzymes in liver disease

scientific article published on 28 July 2009

Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.

scientific article published on 18 April 2017

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

scientific article

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network

scientific article published on 4 October 2017

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease

scientific article published on 20 October 2016

Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis

scientific article published on 25 June 2009

Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study

scientific article published on 09 August 2017

Is global elimination of HCV realistic?

scientific article published in February 2018

Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation.

scientific article published on July 2012

Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis

article

Models for non-alcoholic fatty liver disease: a link with vascular risk.

scientific article published on January 2008

Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis

scientific article published on 12 August 2013

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

scientific article

Muscle cramps in cirrhosis: the therapeutic value of quinine. Is it underused?

scientific article published on 20 March 2008

NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis

scientific article

Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) â lack of interference by iron deposition

scientific article published in February 2010

Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis.

scientific article

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

scientific article published on 27 June 2007

Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.

scientific article published on 28 July 2008

Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects

scientific article

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.

scientific article

Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study)

scientific article published on 20 September 2019

Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection

scientific article published on 27 October 2009

Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis

scientific article published on 11 January 2015

RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit

scientific article published on 01 October 2009

Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?

scientific article published on February 2014

Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye.

scientific article published on June 2015

Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.

scientific article published on 25 July 2012

Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients

scientific article published on 06 March 2011

Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population

scientific article published on 23 March 2016

TACE versus TAE as therapy for hepatocellular carcinoma

scientific article published on October 2008

The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis.

scientific article

Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.

scientific article published on 14 October 2014

Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis

scientific article published on 15 September 2013

Why do I treat my patients with mild hepatitis C?

scientific article published on January 2016

List of works by Vincenza Calvaruso

A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation

Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy

An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers.

Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication.

Clinical implications of the hyperdynamic syndrome in cirrhosis

Coagulation and fibrosis in chronic liver disease

Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis

Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis.

Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis

Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C.

Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient.

Critically ill patients with cirrhosis and low serum sodium

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial

Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation.

Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation

Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?

Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension

Efficacy and safety of Boceprevir-based therapy in HCVG1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP survey

Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy

Fecal Calprotectin in Clinical Practice

Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance.

Fibrosis in chronic viral hepatitis.

Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy.

HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.

HBV recurrence after HCV clearance on DAAs: Sometimes they come back

Hepassocin as a treatment for fulminant hepatic failure: will it translate from rats to human?

Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis

Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis

Hepatocellular carcinoma and direct-acting antivirals: A never ending story?

High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma

Histological subclassification of cirrhosis

IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection

Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin

Immunological alterations in hepatitis C virus infection

Impact of tips preliver transplantation for the outcome posttransplantation

Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model

Implication of normal liver enzymes in liver disease

Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease

Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis

Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study

Is global elimination of HCV realistic?

Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation.

Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis

Models for non-alcoholic fatty liver disease: a link with vascular risk.

Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

Muscle cramps in cirrhosis: the therapeutic value of quinine. Is it underused?

NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis

Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) â lack of interference by iron deposition

Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis.

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.

Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.

Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study)

Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection

Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis

RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit

Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?

Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye.

Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.

Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients

Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population

TACE versus TAE as therapy for hepatocellular carcinoma

The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis.

Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.

Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis

Why do I treat my patients with mild hepatitis C?